Cargando…

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019

PURPOSE: To assess the antimicrobial activities of ceftazidime/avibactam (CAZ/AVI) and aztreonam/avibactam (ATM/AVI) against carbapenem-resistant Enterobacteriaceae (CRE) isolates collected from three secondary hospitals in Southwest China between 2018 and 2019. MATERIALS AND METHODS: A total of 120...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Chunhong, Wei, Jie, Shan, Baoju, Chen, Xian, Wang, Deqiang, Niu, Siqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567573/
https://www.ncbi.nlm.nih.gov/pubmed/33116675
http://dx.doi.org/10.2147/IDR.S273989
_version_ 1783596353309376512
author Zou, Chunhong
Wei, Jie
Shan, Baoju
Chen, Xian
Wang, Deqiang
Niu, Siqiang
author_facet Zou, Chunhong
Wei, Jie
Shan, Baoju
Chen, Xian
Wang, Deqiang
Niu, Siqiang
author_sort Zou, Chunhong
collection PubMed
description PURPOSE: To assess the antimicrobial activities of ceftazidime/avibactam (CAZ/AVI) and aztreonam/avibactam (ATM/AVI) against carbapenem-resistant Enterobacteriaceae (CRE) isolates collected from three secondary hospitals in Southwest China between 2018 and 2019. MATERIALS AND METHODS: A total of 120 unique CRE clinical isolates were collected and carbapenemase genes were detected using PCR. Antimicrobial susceptibility was determined using standard broth microdilution method and the results were interpreted according to CLSI breakpoints. RESULTS: The 120 carbapenem-resistant strains included 92 Klebsiella pneumoniae, 10 Escherichia coli, 10 Enterobacter cloacae, five Klebsiella aerogenes, and three Klebsiella oxytoca isolates. Seventy-four percent of these 120 CRE isolates were collected from patients located in non-ICUs; 65.0% of these CRE isolates were collected from male patients; and 34.2% of these isolates were isolated from respiratory tracts. Four different carbapenemase genes were identified among 103 carbapenemase-producing Enterobacteriaceae (CPE) isolates, including bla(KPC-2) (n=77), bla(NDM-1) (n=16), bla(NDM-5) (n=12) and bla(IMP-4) (n=2). Overall, 21.7%, 37.5%, 40.8%, 75.0%, and 100% of the CRE strains were susceptible to levofloxacin, trimethoprim/sulfamethoxazole, amikacin, CAZ/AVI, and ATM/AVI, respectively. In addition, antimicrobial susceptibility testing showed that 96.7% isolates (n=116) were resistant to aztreonam, and the addition of avibactam (4 mg/L) significantly reduced the MICs of those aztreonam-resistant isolates by more than 128-fold (range: ≤0.125–4 mg/L), and 90.0% (n=108) of total 120 isolates were inhibited at ATM/AVI concentration ≤1 mg/L. CONCLUSION: Our study revealed significant antimicrobial resistance among the CRE isolates against some commonly used antibiotics in three secondary Chinese hospitals. ATM/AVI exhibited potent activity against CRE isolates, including double carbapenemase-producing isolates, whereas CAZ/AVI was active against all KPC producers.
format Online
Article
Text
id pubmed-7567573
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75675732020-10-27 In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019 Zou, Chunhong Wei, Jie Shan, Baoju Chen, Xian Wang, Deqiang Niu, Siqiang Infect Drug Resist Original Research PURPOSE: To assess the antimicrobial activities of ceftazidime/avibactam (CAZ/AVI) and aztreonam/avibactam (ATM/AVI) against carbapenem-resistant Enterobacteriaceae (CRE) isolates collected from three secondary hospitals in Southwest China between 2018 and 2019. MATERIALS AND METHODS: A total of 120 unique CRE clinical isolates were collected and carbapenemase genes were detected using PCR. Antimicrobial susceptibility was determined using standard broth microdilution method and the results were interpreted according to CLSI breakpoints. RESULTS: The 120 carbapenem-resistant strains included 92 Klebsiella pneumoniae, 10 Escherichia coli, 10 Enterobacter cloacae, five Klebsiella aerogenes, and three Klebsiella oxytoca isolates. Seventy-four percent of these 120 CRE isolates were collected from patients located in non-ICUs; 65.0% of these CRE isolates were collected from male patients; and 34.2% of these isolates were isolated from respiratory tracts. Four different carbapenemase genes were identified among 103 carbapenemase-producing Enterobacteriaceae (CPE) isolates, including bla(KPC-2) (n=77), bla(NDM-1) (n=16), bla(NDM-5) (n=12) and bla(IMP-4) (n=2). Overall, 21.7%, 37.5%, 40.8%, 75.0%, and 100% of the CRE strains were susceptible to levofloxacin, trimethoprim/sulfamethoxazole, amikacin, CAZ/AVI, and ATM/AVI, respectively. In addition, antimicrobial susceptibility testing showed that 96.7% isolates (n=116) were resistant to aztreonam, and the addition of avibactam (4 mg/L) significantly reduced the MICs of those aztreonam-resistant isolates by more than 128-fold (range: ≤0.125–4 mg/L), and 90.0% (n=108) of total 120 isolates were inhibited at ATM/AVI concentration ≤1 mg/L. CONCLUSION: Our study revealed significant antimicrobial resistance among the CRE isolates against some commonly used antibiotics in three secondary Chinese hospitals. ATM/AVI exhibited potent activity against CRE isolates, including double carbapenemase-producing isolates, whereas CAZ/AVI was active against all KPC producers. Dove 2020-10-12 /pmc/articles/PMC7567573/ /pubmed/33116675 http://dx.doi.org/10.2147/IDR.S273989 Text en © 2020 Zou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zou, Chunhong
Wei, Jie
Shan, Baoju
Chen, Xian
Wang, Deqiang
Niu, Siqiang
In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
title In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
title_full In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
title_fullStr In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
title_full_unstemmed In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
title_short In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
title_sort in vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant enterobacteriaceae isolates collected from three secondary hospitals in southwest china between 2018 and 2019
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567573/
https://www.ncbi.nlm.nih.gov/pubmed/33116675
http://dx.doi.org/10.2147/IDR.S273989
work_keys_str_mv AT zouchunhong invitroactivityofceftazidimeavibactamandaztreonamavibactamagainstcarbapenemresistantenterobacteriaceaeisolatescollectedfromthreesecondaryhospitalsinsouthwestchinabetween2018and2019
AT weijie invitroactivityofceftazidimeavibactamandaztreonamavibactamagainstcarbapenemresistantenterobacteriaceaeisolatescollectedfromthreesecondaryhospitalsinsouthwestchinabetween2018and2019
AT shanbaoju invitroactivityofceftazidimeavibactamandaztreonamavibactamagainstcarbapenemresistantenterobacteriaceaeisolatescollectedfromthreesecondaryhospitalsinsouthwestchinabetween2018and2019
AT chenxian invitroactivityofceftazidimeavibactamandaztreonamavibactamagainstcarbapenemresistantenterobacteriaceaeisolatescollectedfromthreesecondaryhospitalsinsouthwestchinabetween2018and2019
AT wangdeqiang invitroactivityofceftazidimeavibactamandaztreonamavibactamagainstcarbapenemresistantenterobacteriaceaeisolatescollectedfromthreesecondaryhospitalsinsouthwestchinabetween2018and2019
AT niusiqiang invitroactivityofceftazidimeavibactamandaztreonamavibactamagainstcarbapenemresistantenterobacteriaceaeisolatescollectedfromthreesecondaryhospitalsinsouthwestchinabetween2018and2019